Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGPS1 | O95749 | 6/20 | 0.41 |
| ▸ | FDPS | P14324 | 9/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | SMPD1 | P17405 | 2/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.39 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.39 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL314067 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL315227 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL992535 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL992551 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL314021 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL535649 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL8581895 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL992088 | 1.00 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 | |
| SCHEMBL8330823 | 0.97 | FDPS (0.38) | GGPS1FDPSSMPD1CES2LPAR1 | |
| SCHEMBL10601688 | 0.80 | GGPS1 (0.41) | GGPS1FDPSTSHRTHRBSMPD1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9056313-B2 | Catalysts for the production of hydroxy ether hydrocarbons by vapor phase hydrogenolysis of cyclic acetals and ketals | EASTMAN CHEMICAL COMPANY (US) | 2015-06-16 | — | — | US | disclosed |
| US-9000229-B2 | Production of hydroxy ether hydrocarbons by vapor phase hydrogenolysis of cyclic acetals and ketals | EASTMAN CHEMICAL COMPANY (US) | 2015-04-07 | — | — | US | disclosed |
| WO-2012177602-A1 | PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | EASTMAN CHEMICAL COMPANY (US) | 2012-12-27 | — | — | WO | disclosed |
| WO-2012177484-A1 | CATALYSTS FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | EASTMAN CHEMICAL COMPANY (US) | 2012-12-27 | — | — | WO | disclosed |
| US-20120330067-A1 | CATALYSTS FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | EASTMAN CHEMICAL COMPANY (US) | 2012-12-27 | — | — | US | disclosed |
| US-20120330066-A1 | PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | EASTMAN CHEMICAL COMPANY (US) | 2012-12-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120330067-A1 | CATALYSTS FOR THE PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | SUV39H2, KAT5, SUV39H1 | GGPS1 3463/4885FDPS 4372/4885TSHR 4045/4885 |
| US-20120330066-A1 | PRODUCTION OF HYDROXY ETHER HYDROCARBONS BY VAPOR PHASE HYDROGENOLYSIS OF CYCLIC ACETALS AND KETALS | SUV39H1, HDHD5, SUV39H2 | GGPS1 2823/4885FDPS 3744/4885TSHR 4429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.